Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: results of a randomized controlled trial

J Gastroenterol Hepatol. 2009 May;24(5):736-42. doi: 10.1111/j.1440-1746.2008.05758.x. Epub 2009 Feb 12.

Abstract

Background and aims: This study addresses whether antibiotic prophylaxis is beneficial for acute necrotizing pancreatitis.

Methods: This randomized, controlled trial enrolled 276 patients with severe acute pancreatitis. There were 56 patients with 30% or more necrosis proved by contrast-enhanced computerized tomography who were eligible for randomization: 29 in the study group and 27 in the control group, who received i.v. imipenem-cilastatin (3 x 500 mg/day) within 72 h of the onset of symptoms for 7-14 days, and no antibiotic prophylaxis, respectively. The primary end-point was the incidence of infectious complication. The secondary end-points were mortality, the incidence of necrosectomy for infected necrosis, the incidence of organ complication and hospital courses.

Results: Characteristics of baseline data were similar in the two groups. No significant differences were found in the incidence of infected pancreatic necrosis (37% vs 27.6%), mortality (10.3% vs 14.8%) and the incidence of operative necrosectomy (29.6% vs 34.6%) between the study group and the control group (P > 0.05). The incidence of extrapancreatic infections, organ complications and hospital courses between the groups were also not significantly different. However, a significantly increased incidence of fungal infection was observed in the study group versus the control group (36.1% vs 14.2%, P < 0.05).

Conclusion: There was no benefit in the outcomes when antibiotic prophylaxis was routinely used in patients with acute necrotizing pancreatitis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Antibiotic Prophylaxis* / adverse effects
  • C-Reactive Protein / metabolism
  • Cilastatin / administration & dosage
  • Cilastatin / adverse effects
  • Cilastatin, Imipenem Drug Combination
  • Disease Progression
  • Drug Combinations
  • Female
  • Humans
  • Imipenem / administration & dosage
  • Imipenem / adverse effects
  • Male
  • Middle Aged
  • Mycoses / chemically induced
  • Pancreas / diagnostic imaging
  • Pancreas / drug effects*
  • Pancreas / surgery
  • Pancreatectomy
  • Pancreatitis / complications
  • Pancreatitis / diagnostic imaging
  • Pancreatitis / drug therapy*
  • Pancreatitis / mortality
  • Pancreatitis / surgery
  • Pancreatitis, Acute Necrotizing / diagnostic imaging
  • Pancreatitis, Acute Necrotizing / etiology
  • Pancreatitis, Acute Necrotizing / pathology
  • Pancreatitis, Acute Necrotizing / prevention & control*
  • Pancreatitis, Acute Necrotizing / surgery
  • Patient Selection
  • Severity of Illness Index
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • Cilastatin
  • Imipenem
  • C-Reactive Protein
  • Cilastatin, Imipenem Drug Combination